392 related articles for article (PubMed ID: 33262282)
1. Targeting progesterone signaling prevents metastatic ovarian cancer.
Kim O; Park EY; Kwon SY; Shin S; Emerson RE; Shin YH; DeMayo FJ; Lydon JP; Coffey DM; Hawkins SM; Quilliam LA; Cheon DJ; Fernández FM; Nephew KP; Karpf AR; Widschwendter M; Sood AK; Bast RC; Godwin AK; Miller KD; Cho CH; Kim J
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31993-32004. PubMed ID: 33262282
[TBL] [Abstract][Full Text] [Related]
2. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA
Ponandai-Srinivasan S; Lalitkumar PG; Garcia L; Varghese SJ; Carlson JW; Gemzell-Danielsson K; Floter Radestad A
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):250-261. PubMed ID: 30325501
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
4. Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
Lheureux S; Shaw PA; Karakasis K; Oza AM
Gynecol Oncol; 2015 Aug; 138(2):235-7. PubMed ID: 26072440
[No Abstract] [Full Text] [Related]
5. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
6. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
9. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
[TBL] [Abstract][Full Text] [Related]
10. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Kwon JS; Daniels MS; Sun CC; Lu KH
J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
[TBL] [Abstract][Full Text] [Related]
11. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
12. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
14. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Poole AJ; Li Y; Kim Y; Lin SC; Lee WH; Lee EY
Science; 2006 Dec; 314(5804):1467-70. PubMed ID: 17138902
[TBL] [Abstract][Full Text] [Related]
15. [Prophylactic salpingectomy or salpingo-oophorectomy as an ovarian cancer prevention?].
Chene G; Lamblin G; Le Bail-Carval K; Chabert P; Golfier F; Dauplat J; Deligdisch L; Penault-Llorca F; Mellier G
Presse Med; 2015 Mar; 44(3):317-23. PubMed ID: 25578546
[TBL] [Abstract][Full Text] [Related]
16. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
18. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
Burling MJ; Gamet K; Eva L; Tan AL
Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
[TBL] [Abstract][Full Text] [Related]
19. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
20. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
